The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) poly...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Levine, Ross L., Loriaux, Marc, Huntly, Brian J. P., Loh, Mignon L., Beran, Miroslav, Stoffregen, Eric, Berger, Roland, Clark, Jennifer J., Willis, Stephanie G., Nguyen, Kim T., Flores, Nikki J., Estey, Elihu, Gattermann, Norbert, Armstrong, Scott, Look, A. Thomas, Griffin, James D., Bernard, Olivier A., Heinrich, Michael C., Gilliland, D. Gary, Druker, Brian, Deininger, Michael W. N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The American Society of Hematology 2005
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895066/
https://ncbi.nlm.nih.gov/pubmed/16081687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-05-1898
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg